Złowocka-Perłowska Elżbieta, Baszuk Piotr, Marciniak Wojciech, Derkacz Róża, Tołoczko-Grabarek Aleksandra, Gołębiewska Katarzyna, Słojewski Marcin, Gołąb Adam, Lemiński Artur, Soczawa Michał, Scott Rodney J, Lubiński Jan
Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, 70-204 Szczecin, Poland.
Read-Gene, Grzepnica, ul. Alabastrowa 8, 72-003 Dobra, Poland.
Nutrients. 2025 Mar 8;17(6):944. doi: 10.3390/nu17060944.
Copper (Cu) and zinc (Zn) are essential trace elements, and an imbalance in their levels may influence the progression of cancer. The role of Cu and Zn levels in blood and serum, as well as 10-year survival rates in kidney cancer patients, remains unclear. Our objective was to determine the association between these micronutrients and mortality of kidney cancer patients. In this prospective study, we examined 284 consecutive, unselected kidney cancer patients and assessed their 10-year survival in relation to Cu and Zn levels. : Micronutrient levels were measured using an inductively coupled plasma mass spectrometer. Each patient was categorized into one of four groups based on the distribution of Cu and Zn levels, ranked in increasing order. The multivariable models included factors such as age at diagnosis, gender, smoking history, type of surgery, and histopathological results. : We observed a significantly higher risk of all-cause mortality in patients with the highest blood or serum copper levels compared to those with the lower levels (blood: HR = 4.89; < 0.001; serum: HR = 3.75; < 0.001). With regard to zinc, we found a trend where lower blood or serum zinc levels (I quartile) were associated with higher mortality. Additionally, we identified a significant correlation between the Zn/Cu ratio and mortality. Patients in the lowest Zn/Cu ratio quartile had elevated hazard ratios compared to those in the higher quartile with HRs of 3.05 ( < 0.002) in blood and 5.72 ( < 0.001) in serum. To our knowledge, this study is the first to investigate the relationship between blood and serum levels of copper and zinc and kidney cancer survival.
铜（Cu）和锌（Zn）是必需的微量元素，其水平失衡可能会影响癌症的进展。血液和血清中铜和锌的水平以及肾癌患者的10年生存率仍不清楚。我们的目的是确定这些微量营养素与肾癌患者死亡率之间的关联。在这项前瞻性研究中，我们检查了284例连续的、未经筛选的肾癌患者，并评估了他们与铜和锌水平相关的10年生存率。：使用电感耦合等离子体质谱仪测量微量营养素水平。根据铜和锌水平的分布（按升序排列），将每位患者分为四组之一。多变量模型包括诊断时的年龄、性别、吸烟史、手术类型和组织病理学结果等因素。：我们观察到，与铜水平较低的患者相比，血液或血清铜水平最高的患者全因死亡率风险显著更高（血液：HR = 4.89；<0.001；血清：HR = 3.75；<0.001）。关于锌，我们发现血液或血清锌水平较低（第一四分位数）与较高死亡率之间存在一种趋势。此外，我们确定锌/铜比值与死亡率之间存在显著相关性。锌/铜比值最低四分位数的患者与较高四分位数的患者相比，风险比升高，血液中的HR为3.05（<0.002），血清中的HR为5.72（<0.001）。据我们所知，本研究是首次调查血液和血清中铜和锌水平与肾癌生存率之间的关系。
